Peptide Half-Life Chart: Complete Reference Guide for Researchers (2026)
A comprehensive, up-to-date peptide half-life chart covering 20+ research peptides with storage conditions, reconstituted stability windows, and typical research dose ranges.
Table of Contents
- What Is a Peptide Half-Life Chart?
- Complete Peptide Half-Life Chart (20+ Peptides)
- How to Interpret Half-Life Values
- Storage Temperature and Handling
- Reconstituted Stability Windows
- Understanding Research Dose Ranges
- Categories of Research Peptides
- Best Practices for Peptide Handling
- Frequently Asked Questions
What Is a Peptide Half-Life Chart?
A peptide half-life chart is a reference tool used by laboratory researchers to quickly compare how long different peptides remain biologically active in plasma or buffer systems. Half-life, usually abbreviated as t½, is defined as the time required for the concentration of a substance to decline by 50% from its initial value. In peptide research, it is one of the single most useful numbers to know, because it directly influences dosing frequency in animal models, experimental timing, and the interpretation of pharmacodynamic results.
Peptide half-lives vary enormously. Small, unmodified peptides such as Sermorelin, Tesamorelin, and DSIP are cleaved by serum proteases within minutes, while lipidated or albumin-binding analogs such as Semaglutide, Tirzepatide, and Retatrutide remain detectable for days. This guide compiles the most commonly referenced half-life, storage, and handling values for twenty of the most widely studied research peptides as of 2026.
Complete Peptide Half-Life Chart
The table below summarizes plasma half-life, lyophilized storage temperature, reconstituted stability at 2–8 °C, and typical research dose ranges reported in the peer-reviewed literature and in pharmacokinetic modeling studies. Values are approximate and may vary depending on route of administration, formulation, species, and assay methodology.
| Peptide | Half-Life (t½) | Storage Temp (Lyophilized) | Reconstituted Stability (2–8 °C) | Typical Research Dose Range |
|---|---|---|---|---|
| BPC-157 | ~4 hours | -20 °C | 4–6 weeks | 200–500 mcg/day |
| TB-500 (Thymosin β4 fragment) | ~2–3 hours | -20 °C | 2–4 weeks | 2–2.5 mg weekly |
| GHK-Cu | ~1–2 hours | -20 °C | 3–4 weeks | 1–2 mg/day |
| Retatrutide | ~6 days (~144 h) | -20 °C | 4 weeks | 2–12 mg weekly |
| Semaglutide | ~7 days (~165 h) | -20 °C | 4–6 weeks | 0.25–2.4 mg weekly |
| Tirzepatide | ~5 days (~120 h) | -20 °C | 4 weeks | 2.5–15 mg weekly |
| AOD-9604 | ~30 minutes | -20 °C | 2–3 weeks | 250–300 mcg/day |
| CJC-1295 (no DAC) | ~30 minutes | -20 °C | 2–3 weeks | 100 mcg/day |
| CJC-1295 (with DAC) | ~6–8 days | -20 °C | 3–4 weeks | 1–2 mg weekly |
| Ipamorelin | ~2 hours | -20 °C | 2–3 weeks | 200–300 mcg/day |
| Sermorelin | ~11–20 minutes | -20 °C | 2–3 weeks | 100–500 mcg/day |
| PT-141 (Bremelanotide) | ~2 hours | -20 °C | 4 weeks | 0.75–1.75 mg/dose |
| Epithalon | ~20–30 minutes | -20 °C | 2–3 weeks | 5–10 mg/day |
| MOTS-C | ~1–2 hours | -20 °C | 2–3 weeks | 5–10 mg weekly |
| KPV | ~30 minutes | -20 °C | 2–3 weeks | 200–500 mcg/day |
| Thymosin Alpha-1 | ~2 hours | -20 °C | 3–4 weeks | 1.6 mg twice weekly |
| Tesamorelin | ~26 minutes | -20 °C | 3–4 weeks | 1–2 mg/day |
| DSIP (Delta Sleep-Inducing Peptide) | ~7–20 minutes | -20 °C | 2–3 weeks | 100–500 mcg/day |
| Selank | ~4–6 minutes (IV); longer intranasal | -20 °C | 3–4 weeks | 250–500 mcg/day |
| Semax | ~5–20 minutes | -20 °C | 3–4 weeks | 200–600 mcg/day |
| Melanotan II | ~33 hours | -20 °C | 4–6 weeks | 0.5–1 mg/dose |
All values are literature-reported approximations for research reference. Actual stability and pharmacokinetics depend on formulation, purity, diluent, and storage conditions.
How to Interpret Half-Life Values
When reviewing a peptide half-life chart, it is important to remember that half-life is a statistical descriptor, not a hard cutoff. After one half-life, 50% of the peptide remains; after four to five half-lives, less than 5% remains, which is usually the point at which pharmacological effects are considered negligible. Researchers modeling repeat-dose experiments generally aim to reach steady-state concentrations after four to five half-lives of continuous administration.
Peptides with very short half-lives, such as Sermorelin and Tesamorelin, produce sharp, pulsatile signals that mimic physiological release patterns, which is often desirable when studying hypothalamic feedback loops. Peptides with long half-lives, such as Semaglutide and Retatrutide, produce smooth, sustained exposure that is favored for weekly-dosing pharmacokinetic and metabolic studies.
Storage Temperature and Handling
Virtually every research peptide should be stored lyophilized at -20 °C or colder in a sealed, desiccated environment. Some laboratories prefer -80 °C storage for highly hydrolytically sensitive sequences or when the peptide will be kept for more than a year. Repeated temperature cycling should be avoided, as moisture condensation on cold vials can initiate hydrolysis of amide and disulfide bonds.
Light exposure also contributes to degradation, particularly for peptides containing tryptophan, tyrosine, methionine, or cysteine residues. Amber vials and opaque storage boxes are recommended. Peptides should always be brought to room temperature in a sealed container before opening to prevent water vapor from condensing on the powder, which would otherwise accelerate degradation of the reconstituted solution.
Reconstituted Stability Windows
The reconstituted stability window is the practical shelf life of a peptide after it has been dissolved in bacteriostatic water, sterile saline, or another suitable diluent. Once reconstituted, peptides begin to experience hydrolytic and enzymatic degradation, even when refrigerated. Most research peptides retain acceptable potency for two to six weeks at 2–8 °C, with stabilized long-acting analogs at the upper end of that range and unmodified peptides at the lower end.
Bacteriostatic water containing 0.9% benzyl alcohol is generally preferred over plain sterile water because it suppresses microbial growth during multi-dose use. Researchers should always inspect reconstituted solutions for cloudiness, particulate formation, or color change before use, and discard any solution that appears degraded regardless of how recently it was prepared.
Understanding Research Dose Ranges
The dose ranges shown in the chart reflect commonly reported laboratory research values and are not clinical recommendations. Dose ranges are often species- and model-dependent, with rodent studies using body-weight-normalized doses (mcg/kg or mg/kg) that may be substantially different from the fixed doses used in primate or pharmacokinetic models. When designing experiments, always consult primary literature for the specific model system in use and apply appropriate allometric scaling.
Categories of Research Peptides
The peptides in this chart fall into several broad functional categories. Growth hormone secretagogues and GHRH analogs include Sermorelin, Tesamorelin, Ipamorelin, and CJC-1295. Incretin mimetics and metabolic peptides include Semaglutide, Tirzepatide, and Retatrutide. Tissue-repair and cytoprotective peptides include BPC-157, TB-500, and GHK-Cu. Immunomodulators include Thymosin Alpha-1 and KPV. Nootropic and neuropeptides include Selank, Semax, and DSIP. Melanocortin agonists include PT-141 and Melanotan II, while mitochondrial and longevity peptides include MOTS-C and Epithalon. Each category has characteristic pharmacokinetic behavior that is reflected in the half-life column of the chart above.
Best Practices for Peptide Handling
Researchers working with peptides should observe a few universal best practices. Always use clean, sterile technique when reconstituting lyophilized powder, and add diluent gently down the side of the vial rather than directly onto the peptide cake to minimize foaming and denaturation. Do not shake vials vigorously; gently swirl until fully dissolved. Label every reconstituted vial with the date, concentration, and diluent used. Keep a peptide log that records lot numbers, reconstitution dates, and stability observations so that results can be reproduced and anomalies traced back to a specific batch.
Finally, remember that the most reliable half-life and stability data are always those published in peer-reviewed pharmacokinetic studies for the specific peptide, formulation, and species of interest. This chart is a starting point and a convenient reference, not a substitute for primary literature review.
Frequently Asked Questions
What is a peptide half-life chart and why does it matter?
A peptide half-life chart lists the time required for the plasma concentration of each peptide to decrease by 50% after administration. Researchers use half-life data to understand dosing frequency, expected duration of biological activity, and clearance kinetics. Because half-life varies from a few minutes to several days, accurate reference data is essential for experimental design.
How should lyophilized peptides be stored for long-term stability?
Lyophilized peptides should be stored at -20 °C or colder in a sealed, desiccated container protected from light and humidity. Under these conditions most research peptides remain stable for 12 to 24 months. Storing lyophilized powder at -80 °C can extend stability further for particularly sensitive sequences.
How long are peptides stable after reconstitution?
Once reconstituted in bacteriostatic water or sterile saline, most peptides remain stable for 2 to 6 weeks when refrigerated at 2–8 °C. Hydrolytically sensitive peptides such as Sermorelin and AOD-9604 degrade faster and should be used within 2–3 weeks, while stabilized analogs like Semaglutide and Tirzepatide can retain potency for 4–6 weeks.
Which peptide has the longest half-life on this chart?
Retatrutide has one of the longest plasma half-lives on this chart at approximately 6 days, followed closely by Semaglutide at roughly 7 days and Tirzepatide at about 5 days. These long half-lives are the result of fatty acid conjugation and albumin binding, which delay renal and enzymatic clearance.
Which peptide has the shortest half-life on this chart?
Sermorelin and Tesamorelin have extremely short half-lives of roughly 11–26 minutes because they are minimally modified growth hormone-releasing hormone analogs that are rapidly cleaved by dipeptidyl peptidase-4 and other serum proteases.
Does CJC-1295 with DAC have a longer half-life than CJC-1295 without DAC?
Yes. CJC-1295 without DAC (also called Modified GRF 1-29) has a half-life of approximately 30 minutes, while CJC-1295 with DAC binds to serum albumin via a maleimide linker and extends the half-life to roughly 6–8 days, allowing weekly rather than daily dosing in research models.
Can reconstituted peptides be frozen for later use?
Freezing reconstituted peptides is generally discouraged because freeze-thaw cycles can cause aggregation and loss of activity. If long-term storage of a reconstituted solution is required, researchers typically aliquot the solution into single-use vials, snap-freeze at -80 °C, and thaw only once before use. Sterile saline is preferred over bacteriostatic water for frozen aliquots.
Are the research dose ranges listed on this chart safe for human use?
No. The dose ranges on this chart are provided strictly for laboratory research and in-vitro reference purposes. None of the peptides listed are intended for human consumption, clinical treatment, or self-administration. Researchers must comply with all applicable institutional, state, and federal regulations governing the use of research chemicals.